JP2020523408A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523408A5 JP2020523408A5 JP2020517619A JP2020517619A JP2020523408A5 JP 2020523408 A5 JP2020523408 A5 JP 2020523408A5 JP 2020517619 A JP2020517619 A JP 2020517619A JP 2020517619 A JP2020517619 A JP 2020517619A JP 2020523408 A5 JP2020523408 A5 JP 2020523408A5
- Authority
- JP
- Japan
- Prior art keywords
- cardiovascular
- pharmaceutical composition
- disease
- patient
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 32
- 208000010125 myocardial infarction Diseases 0.000 claims description 30
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 24
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 22
- 230000007211 cardiovascular event Effects 0.000 claims description 14
- 206010020772 Hypertension Diseases 0.000 claims description 8
- 229960001713 canagliflozin Drugs 0.000 claims description 8
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 claims description 8
- 206010002383 Angina Pectoris Diseases 0.000 claims description 7
- 206010019280 Heart failures Diseases 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 6
- 208000007888 Sinus Tachycardia Diseases 0.000 claims description 6
- 230000002411 adverse Effects 0.000 claims description 6
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- 206010003119 arrhythmia Diseases 0.000 claims description 5
- 206010001580 Albuminuria Diseases 0.000 claims description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 4
- 206010027525 Microalbuminuria Diseases 0.000 claims description 4
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 4
- 206010002329 Aneurysm Diseases 0.000 claims description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 2
- 208000001871 Tachycardia Diseases 0.000 claims description 2
- 206010065341 Ventricular tachyarrhythmia Diseases 0.000 claims description 2
- 210000003423 ankle Anatomy 0.000 claims description 2
- 210000001367 artery Anatomy 0.000 claims description 2
- 230000036772 blood pressure Effects 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 238000007887 coronary angioplasty Methods 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000015210 hypertensive heart disease Diseases 0.000 claims description 2
- 238000003384 imaging method Methods 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 230000000302 ischemic effect Effects 0.000 claims description 2
- 210000003141 lower extremity Anatomy 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 208000031225 myocardial ischemia Diseases 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 208000037804 stenosis Diseases 0.000 claims description 2
- 230000036262 stenosis Effects 0.000 claims description 2
- 230000006794 tachycardia Effects 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- 210000002073 venous valve Anatomy 0.000 claims description 2
- 208000003663 ventricular fibrillation Diseases 0.000 claims description 2
- 206010047302 ventricular tachycardia Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 230000006793 arrhythmia Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023077544A JP2023113644A (ja) | 2017-06-12 | 2023-05-10 | ２型糖尿病の患者における心血管イベントの低減又は予防方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762518547P | 2017-06-12 | 2017-06-12 | |
| US62/518,547 | 2017-06-12 | ||
| PCT/IB2018/054208 WO2018229630A1 (en) | 2017-06-12 | 2018-06-11 | Method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023077544A Division JP2023113644A (ja) | 2017-06-12 | 2023-05-10 | ２型糖尿病の患者における心血管イベントの低減又は予防方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020523408A JP2020523408A (ja) | 2020-08-06 |
| JP2020523408A5 true JP2020523408A5 (enExample) | 2021-07-26 |
| JPWO2018229630A5 JPWO2018229630A5 (enExample) | 2022-09-27 |
Family
ID=62916717
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517619A Pending JP2020523408A (ja) | 2017-06-12 | 2018-06-11 | ２型糖尿病の患者における心血管イベントの低減又は予防方法 |
| JP2023077544A Withdrawn JP2023113644A (ja) | 2017-06-12 | 2023-05-10 | ２型糖尿病の患者における心血管イベントの低減又は予防方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023077544A Withdrawn JP2023113644A (ja) | 2017-06-12 | 2023-05-10 | ２型糖尿病の患者における心血管イベントの低減又は予防方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20180353470A1 (enExample) |
| EP (1) | EP3638250A1 (enExample) |
| JP (2) | JP2020523408A (enExample) |
| KR (1) | KR20200014406A (enExample) |
| CN (1) | CN110740735A (enExample) |
| AU (1) | AU2018283781B2 (enExample) |
| BR (1) | BR112019026120A2 (enExample) |
| CA (1) | CA3066874A1 (enExample) |
| CO (1) | CO2019013940A2 (enExample) |
| EA (1) | EA202090028A1 (enExample) |
| IL (1) | IL271100A (enExample) |
| MX (1) | MX2019014988A (enExample) |
| TW (1) | TWI835735B (enExample) |
| UA (1) | UA127987C2 (enExample) |
| WO (1) | WO2018229630A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI827184B (zh) * | 2021-08-03 | 2023-12-21 | 國立政治大學 | 第2型糖尿病併發症的風險評估系統與方法 |
| CN117085009B (zh) * | 2023-10-20 | 2024-01-30 | 首都医科大学附属北京天坛医院 | 卡格列净对急性缺血性卒中的治疗作用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2514756B1 (en) | 2003-08-01 | 2014-12-17 | Mitsubishi Tanabe Pharma Corporation | Novel compounds having inhibitory activity against sodium-dependant glucose transporter |
| UY30730A1 (es) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
| DK2385374T4 (en) * | 2010-05-05 | 2018-04-30 | Zora Biosciences Oy | LIPIDOMICS BIOMARKERS FOR ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE |
| CN102985075A (zh) * | 2010-05-11 | 2013-03-20 | 田边三菱制药株式会社 | 含卡纳格列净的片剂 |
| US20160000816A1 (en) * | 2013-04-05 | 2016-01-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CA2812016A1 (en) * | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CA2938406A1 (en) * | 2014-01-31 | 2015-08-06 | Janssen Pharmaceutica Nv | Methods for the treatment and prevention of renal disorders and fatty liver disorders |
| US20170071970A1 (en) * | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
-
2018
- 2018-06-08 TW TW107119774A patent/TWI835735B/zh active
- 2018-06-11 JP JP2020517619A patent/JP2020523408A/ja active Pending
- 2018-06-11 US US16/004,607 patent/US20180353470A1/en not_active Abandoned
- 2018-06-11 KR KR1020207000103A patent/KR20200014406A/ko not_active Ceased
- 2018-06-11 AU AU2018283781A patent/AU2018283781B2/en active Active
- 2018-06-11 WO PCT/IB2018/054208 patent/WO2018229630A1/en not_active Ceased
- 2018-06-11 CA CA3066874A patent/CA3066874A1/en active Pending
- 2018-06-11 UA UAA202000168A patent/UA127987C2/uk unknown
- 2018-06-11 MX MX2019014988A patent/MX2019014988A/es unknown
- 2018-06-11 CN CN201880039211.2A patent/CN110740735A/zh active Pending
- 2018-06-11 BR BR112019026120-6A patent/BR112019026120A2/pt not_active Application Discontinuation
- 2018-06-11 EA EA202090028A patent/EA202090028A1/ru unknown
- 2018-06-11 EP EP18740894.3A patent/EP3638250A1/en active Pending
-
2019
- 2019-12-02 IL IL271100A patent/IL271100A/en unknown
- 2019-12-11 CO CONC2019/0013940A patent/CO2019013940A2/es unknown
-
2020
- 2020-09-15 US US17/021,370 patent/US20210000792A1/en not_active Abandoned
-
2023
- 2023-05-10 JP JP2023077544A patent/JP2023113644A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539164A5 (enExample) | ||
| Bayiz et al. | Percutaneous aspiration thrombectomy in treatment of massive pulmonary embolism | |
| HRP20220058T1 (hr) | Sastavi i metode za smanjenje velikih neželjenih kardiovaskularnih događaja | |
| Quah et al. | The management of the older adult patient with anomalous left coronary artery from the pulmonary artery syndrome: a presentation of two cases and review of the literature | |
| Kim et al. | Long-term comparison of apical versus asymmetric hypertrophic cardiomyopathy | |
| JP2020523408A5 (enExample) | ||
| Le Berre et al. | Anomalous origin of the left coronary artery from the pulmonary artery presenting in adulthood: a French nationwide retrospective study | |
| JPWO2021097120A5 (enExample) | ||
| Downar et al. | Outcomes after “unroofing” of a myocardial bridge of the left anterior descending coronary artery in children with hypertrophic cardiomyopathy | |
| Turazza et al. | Is anticoagulation therapy underused in elderly patients with atrial fibrillation? | |
| Rodríguez-Diez et al. | Joint Mexican position document on the treatment of atrial fibrillation | |
| Foussas | Acute coronary syndromes and comorbidities | |
| SINGLA et al. | Proportion of Myocardial Bridge in a Tertiary Care Hospital of North India: A Retrospective Observational Study. | |
| Nasser et al. | Late-presenting complete heart block after pediatric cardiac surgery | |
| Chauhan et al. | Prevalence of silent myocardial ischemia in type 2 diabetes mellitus with microalbuminuria | |
| Sadeghian et al. | Short QT syndrome and idiopathic ventricular tachycardia in a 28-year-old young man: a potential disease-specific link? | |
| İlter et al. | Multivessel coronary-cameral fistulas associated with ventricular fibrillation: an unusual case | |
| Sneineh | Effect of Obesity on Car-diovascular System: Literature Review | |
| Farshid et al. | Nurse-led, protocol-based atrial fibrillation clinic results in excellent compliance with guidelines | |
| Sheng et al. | Review on sudden deaths due to cardiac abnormalities | |
| Das et al. | Atypically presented acute coronary syndrome, Wellen’s syndrome-A case report | |
| Durcan | Stroke Prevention in the Elderly | |
| Kim et al. | Epsilon Wave Masked by ST-Segment Elevation After Cardioversion From Sustained Ventricular Tachycardia: An Exceptional Manifestation of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy | |
| Aursulesei et al. | CHEST TRAUMA: THE DROP THAT FILLED THE GLASS | |
| Tsunoda et al. | Left ventricular free wall rupture associated with a combination of acute myocardial infarction and stress-provoked cardiomyopathy: An autopsy case |